LANDSCAPE ANALYSIS OF THE NEOEPITOPE-SPECIFIC T CELL RESPONSES IN PATIENTS WITH AND WITHOUT CLINICAL BENEFIT FROM IMMUNE CHECKPOINT BLOCKADE THERAPYJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
DELTA-1: A GLOBAL, MULTICENTER, PHASE 2 STUDY OF ITIL-168, AN UNRESTRICTED AUTOLOGOUS TUMORINFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, IN ADULT PATIENTS WITH ADVANCED CUTANEOUS MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
BIODISTRIBUTION AND SHEDDING ANALYSIS FOLLOWING TREATMENT WITH RP1 ONCOLYTIC IMMUNOTHERAPY IN THE SKIN CANCER PATIENTS FROM THE IGNYTE CLINICAL TRIALJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
IMMUNE BIOMARKER ANALYSIS OF RP1 IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-071OA
INTERIM CLINICAL UPDATE OF THE PHASE 1B TRIAL OF ATRC-101 AS MONOTHERAPY OR IN COMBINATION WITH PEMBROLIZUMAB FOR SELECT ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-070OA
COM701 PLUS NIVOLUMAB DEMONSTRATES PRELIMINARY ANTITUMOR ACTIVITY AND IMMUNE MODULATION OF TUMOR MICROENVIRONMENT IN PATIENTS WITH METASTATIC MSS-CRC AND LIVER METASTASESJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62022-11-072OA
A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal TumorsCLINICAL CANCER RESEARCHIF10.22022-01-0530OA
PRELIMINARY CLINICAL EXPERIENCE WITH XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-1014OA
DELTA-1: A GLOBAL, MULTICENTER PHASE 2 STUDY OF ITIL-168, AN UNRESTRICTED AUTOLOGOUS TUMOR-INFILTRATING LYMPHOCYTE (TIL) CELL THERAPY, IN ADULT PATIENTS WITH ADVANCED CUTANEOUS MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-103OA
FINAL ANALYSIS: PHASE 1B STUDY INVESTIGATING INTRATUMORAL INJECTION OF TOLL-LIKE RECEPTOR 9 AGONIST VIDUTOLIMOD ± PEMBROLIZUMAB IN PATIENTS WITH PD-1 BLOCKADE-REFRACTORY MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62021-11-106OA
UPDATED CLINICAL DATA FROM THE SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) EXPANSION COHORT OF AN ONGOING PH1/1B STUDY OF EGANELISIB (FORMERLY IPI-549) IN COMBINATION WITH NIVOLUMABJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-105PREAI
PRELIMINARY SAFETY, PHARMACOKINETICS/PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF XMAB20717, A PD-1 X CTLA-4 BISPECIFIC ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-12-107OAAI
UPDATED CLINICAL DATA FROM THE MELANOMA EXPANSION COHORT OF AN ONGOING PH1/1B STUDY OF EGANELISIB (FORMERLY IPI-549) IN COMBINATION WITH NIVOLUMABJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-097PREAI
A PHASE 1 EVALUATION OF TEBOTELIMAB, A BISPECIFIC PD-1 X LAG-3 DART® MOLECULE, IN COMBINATION WITH MARGETUXIMAB IN PATIENTS WITH ADVANCED HER2+NEOPLASMSJOURNAL FOR IMMUNOTHERAPY OF CANCERIF10.62020-11-099PREAI
A Phase II Trial of 5-Day Neoadjuvant Radiotherapy for Patients with High-Risk Primary Soft Tissue SarcomaCLINICAL CANCER RESEARCHIF10.22020-04-1573OAAI
A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without IpilimumabCLINICAL CANCER RESEARCHIF10.22019-04-0172OAAI
个人简介
教育背景
工作经历
荣誉奖项
未登录.png){kind=icon}
未登录个人简介教育背景工作经历荣誉奖项
研究方向